A Sweet Dream with SGLT2 Inhibitors

Glucose is an osmotic agent in the peritoneal dialysis fluid (PDF) to absorb water, sodium and other toxins. absorption from PDF blood impairs (PD) efficiency cause glycemic burden. This extra load leads poor control diabetic patients with PD program. Studies have shown sodium-glucose co-transporter (SGLT)-2 expression mesothelial cells. Blockade of SGLT reduced glucose increment increased retention mice. In rat models, it was that high promotes fibrosis by upregulating transporter (GLUT) SGLT, addition phlorizin downregulation GLUT degeneration. According these information, we want share our experience using empagliflozin a controlled type 2 patient, who on program for end-stage renal disease. We hypothesized if administer patient can reduce burden caused increase ultrafiltration volume.